Sep 20, 2023 | Press Release
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARA™ (momelotinib). OJJAARA, approved by the U.S. Food and Drug Administration...
Aug 31, 2023 | Video Transcripts
Risk-Based Care: Personalized care for better patient outcomes Daniel Weaver, BSN, RN, Director, Clinical Innovation and Strategy, Biologics by McKesson: When patients are referred to Biologics by McKesson, it’s during one of the worst times of their...
Aug 31, 2023 | Video Transcripts
Risk-Based Care: Personalized care for better outcomes | Dan & Porscha Daniel Weaver, BSN, RN, Director, Clinical Innovation and Strategy, Biologics by McKesson: When patients are referred to Biologics by McKesson, it’s during one of the worst times of their...
Aug 4, 2023 | Press Release
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA® (quizartinib). VANFLYTA is indicated for use in...
Jun 28, 2023 | Patient Advocacy, Resources
Ela Lourido, Vice President and General Manager, Specialty Pharmacy Services Research shows that Biologics by McKesson’s pioneering risk-based care program maximizes patients’ time on therapy, leading to better oncology patient outcomes. Now, its partnership with...
